https://www.pharmaradar360.com/article/minister-mulls-establishing-national-network-to-collect-expired-medicines-preven-698e453a5f92ac63Pharma Surgeen2026-07-08T11:17:00.000ZMinister mulls establishing national network to collect expired medicines, prevent recirculationhttps://www.pharmaradar360.com/article/letter-to-the-chair-of-the-food-standards-agency-6bc2df2e1d3b54efPharma Surgeen2026-07-08T11:00:01.000ZLetter to the chair of the Food Standards Agencyhttps://www.pharmaradar360.com/article/food-standards-agency-fsa-economic-growth-goals-ef2f7dbf3dbf38abPharma Surgeen2026-07-08T11:00:01.000ZFood Standards Agency (FSA) economic growth goalshttps://www.pharmaradar360.com/article/fsa-mhra-and-nice-economic-growth-goals-0e0f299be89b45f6Pharma Surgeen2026-07-08T11:00:01.000ZFSA, MHRA and NICE economic growth goalshttps://www.pharmaradar360.com/article/national-institute-for-health-and-care-excellence-nice-economic-growth-goals-88099fabb5625953Pharma Surgeen2026-07-08T11:00:00.000ZNational Institute for Health and Care Excellence (NICE) economic growth goalshttps://www.pharmaradar360.com/article/policy-paper-medicines-and-healthcare-products-regulatory-agency-mhra-economic-g-c0ca8208ee7f614bPharma Surgeen2026-07-08T11:00:00.000ZPolicy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goalshttps://www.pharmaradar360.com/article/fda-feedback-pushes-okyo-pharma-into-phase-3-eye-pain-study-08287565b0a5ffc4Pharma Surgeen2026-07-08T11:00:00.000ZFDA feedback pushes OKYO Pharma into Phase 3 eye-pain studyhttps://www.pharmaradar360.com/article/keenova-s-xiaflex-met-phase-3-goals-in-foot-disorder-trial-ceb29c14c9129a72Pharma Surgeen2026-07-08T11:00:00.000ZKeenova's XIAFLEX met Phase 3 goals in foot disorder trialhttps://www.pharmaradar360.com/article/former-merck-and-nasa-leaders-bring-strategic-expertise-to-spacemd-amid-rising-d-8d67dfcff2cdddecPharma Surgeen2026-07-08T11:00:00.000ZFormer Merck and NASA Leaders Bring Strategic Expertise to SpaceMD Amid Rising Demand for its In-Space Pharmaceutical Development Capabilitieshttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-is-up-7-4-after-index-migration-to-russell-2000-a-002aac08317669d2Pharma Surgeen2026-07-08T10:35:19.000ZUltragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value Benchmarks - Has The Bull Case Changed?https://www.pharmaradar360.com/article/looking-after-children-and-those-in-early-years-settings-before-and-during-hot-w-5472a0a61f54d041Pharma Surgeen2026-07-08T10:33:01.000ZLooking after children and those in early years settings before and during hot weather: teachers and other educational professionalshttps://www.pharmaradar360.com/article/novo-nordisk-signs-pact-with-vivani-for-long-lasting-semaglutide-implant-27a367a14db8bfc5Pharma Surgeen2026-07-08T10:15:56.000ZNovo Nordisk signs pact with Vivani for long-lasting semaglutide implanthttps://www.pharmaradar360.com/article/meningococcal-reference-unit-request-form-ceafb7601bb3e0b8Pharma Surgeen2026-07-08T10:12:02.000ZMeningococcal reference unit request formhttps://www.pharmaradar360.com/article/life-sciences-tools-services-stocks-q1-results-benchmarking-10x-genomics-nasdaq-6afbb3c2806af5eaPharma Surgeen2026-07-08T10:06:43.000ZLife Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)https://www.pharmaradar360.com/article/meningococcal-reference-unit-mru-user-manual-0adcf7a237409564Pharma Surgeen2026-07-08T10:03:36.000ZMeningococcal reference unit (MRU): user manualhttps://www.pharmaradar360.com/article/us-biotech-firm-raises-multi-million-series-b-to-scale-astaxanthin-production-427a35ee79dfb406Pharma Surgeen2026-07-08T09:45:00.000ZUS biotech firm raises multi-million series B to scale astaxanthin productionhttps://www.pharmaradar360.com/article/india-renews-push-for-pharma-market-access-in-china-2372cab3c3b7967bPharma Surgeen2026-07-08T09:45:00.000ZIndia renews push for pharma market access in Chinahttps://www.pharmaradar360.com/article/register-medical-devices-to-place-on-the-market-5d9542deb10b4ffbPharma Surgeen2026-07-08T09:38:38.000ZRegister medical devices to place on the markethttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-timing-pharmaceutical-co-ltd-tpex-6659-f08b02814bf569f2Pharma Surgeen2026-07-08T09:18:49.000ZEnterprise value to EBITDA forward of Timing Pharmaceutical Co. Ltd. – TPEX:6659https://www.pharmaradar360.com/article/new-hospital-programme-annual-report-financial-year-2025-to-2026-c61c57596ef1d3e7Pharma Surgeen2026-07-08T09:13:59.000ZNew Hospital Programme annual report: financial year 2025 to 2026https://www.pharmaradar360.com/article/cover-vaccine-coverage-statistics-data-submission-and-publication-dates-66e32106701ccc1bPharma Surgeen2026-07-08T09:10:31.000ZCOVER vaccine coverage statistics: data submission and publication dateshttps://www.pharmaradar360.com/article/three-biotech-tenants-move-into-former-athenahealth-hq-3760d6c98e422a8cPharma Surgeen2026-07-08T09:00:00.000ZThree biotech tenants move into former athenahealth HQhttps://www.pharmaradar360.com/article/is-biomarin-pharmaceutical-bmrn-still-below-fair-value-after-its-russell-index-a-09ac0916c1c7fd81Pharma Surgeen2026-07-08T08:38:50.000ZIs BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?https://www.pharmaradar360.com/article/abl-bio-advances-abl111-to-phase-3-in-first-line-gastric-cancer-paving-the-way-f-2a7eec91771feb0bPharma Surgeen2026-07-08T08:37:16.000ZABL Bio advances ABL111 to Phase 3 in first-line gastric cancer, paving the way for 4-1BB platform licensing-outhttps://www.pharmaradar360.com/article/helix-opens-genomic-cohorts-to-astrazeneca-cdae4d4c2710ead3Pharma Surgeen2026-07-08T08:17:40.000ZHelix opens genomic cohorts to AstraZenecahttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-hunan-er-kang-pharmaceutical-co-ltd-class-a-12b48f10dc97a906Pharma Surgeen2026-07-08T08:14:43.000ZEnterprise value to EBIT forward of Hunan Er-Kang Pharmaceutical Co., Ltd. Class A – SZSE:300267https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-kobayashi-pharmaceutical-co-ltd-tse-4967-46d68894aa2f619cPharma Surgeen2026-07-08T08:13:18.000ZEnterprise value to revenue forward of Kobayashi Pharmaceutical Co., Ltd. – TSE:4967https://www.pharmaradar360.com/article/always-one-step-ahead-anne-petit-on-making-medicines-happen-99953b4068537be6Pharma Surgeen2026-07-08T07:57:35.000ZAlways one step ahead: Anne Petit on making medicines happenhttps://www.pharmaradar360.com/article/new-cancer-drug-vepdegestrant-gets-fda-approval-3cca99892162c399Pharma Surgeen2026-07-08T07:07:11.000ZNew Cancer Drug Vepdegestrant Gets FDA Approvalhttps://www.pharmaradar360.com/article/1-2026-0fe160449905d401Pharma Surgeen2026-07-08T06:54:42.000ZΤελικές Προτεινόμενες _ Νέα 1ου Τριμήνου 2026 _ Ανατιμολόγηση προϊόντων αναφοράς λόγω λήξης της προστασίας δεδομένων τουςhttps://www.pharmaradar360.com/article/fda-confirms-single-phase-3-trial-sufficient-for-ath434-nda-in-msa-fa63cdd450a0c869Pharma Surgeen2026-07-08T06:54:09.000ZFDA Confirms Single Phase 3 Trial Sufficient for ATH434 NDA in MSAhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-29-report-data-to-week-28-dat-3eecc552c8c5e93ePharma Surgeen2026-07-08T06:49:38.000ZNational flu and COVID-19 surveillance report, week 29 report: data to week 28 (data up to 12 July 2026)https://www.pharmaradar360.com/article/biotech-double-winners-outperform-the-market-with-fundamental-tailwinds-poised-t-e95e5ff58e42d060Pharma Surgeen2026-07-08T06:42:37.000ZBiotech Double Winners Outperform the Market, With Fundamental Tailwinds Poised to Sustain Momentumhttps://www.pharmaradar360.com/article/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-7be94b2b54c2f9d1Pharma Surgeen2026-07-08T06:37:39.000ZSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®https://www.pharmaradar360.com/article/takeda-completed-issuance-of-new-shares-and-disposal-of-treasury-shares-under-th-de84d12450044281Pharma Surgeen2026-07-08T06:30:36.000ZTakeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/fda-suspends-heera-sweets-fssai-licence-638c7e070bd9ecb5Pharma Surgeen2026-07-08T06:24:22.000ZFDA suspends Heera Sweets’ FSSAI licencehttps://www.pharmaradar360.com/article/first-aid-a-new-idea-for-the-biotech-act-73f597158e4db8d7Pharma Surgeen2026-07-08T06:20:58.000ZFIRST AID: A new idea for the Biotech Acthttps://www.pharmaradar360.com/article/s2g-hatch-backed-biotech-raises-millions-expands-corbion-ties-5454207d3e5e09eaPharma Surgeen2026-07-08T06:05:15.000ZS2G, Hatch-backed biotech raises millions, expands Corbion tieshttps://www.pharmaradar360.com/article/kintara-kins-price-prediction-2025-2026-will-it-rise-433afe050dc6e270Pharma Surgeen2026-07-08T06:04:17.000ZKintara (KINS) Price Prediction 2025–2026: Will It Rise?https://www.pharmaradar360.com/article/avacta-appoints-healthcare-executive-patrick-vink-as-deputy-chairman-of-the-boar-658571a1441a8f91Pharma Surgeen2026-07-08T06:03:17.000ZAvacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directorshttps://www.pharmaradar360.com/article/china-s-biotech-boom-ras-targeted-drugs-challenge-us-dominance-c63082c0233e590aPharma Surgeen2026-07-08T06:00:12.000ZChina’s biotech boom: RAS-targeted drugs challenge US dominancehttps://www.pharmaradar360.com/article/why-is-sichuan-kelun-biotech-stock-sliding-today-5b87bf8c57895db1Pharma Surgeen2026-07-08T05:55:53.000ZWhy is Sichuan Kelun Biotech stock sliding today?https://www.pharmaradar360.com/article/d-d-pharmatech-earns-milestone-as-partner-advances-fap-pet-imaging-agent-into-ph-df5f53eb9fd8ca35Pharma Surgeen2026-07-08T05:24:37.000ZD&D Pharmatech earns milestone as partner advances FAP PET imaging agent into phase 2https://www.pharmaradar360.com/article/woojung-bio-changes-name-to-kolmar-biotech-after-joining-kolmar-group-08ffde28665ecfc1Pharma Surgeen2026-07-08T05:17:10.000ZWoojung Bio changes name to Kolmar BioTech after joining Kolmar Grouphttps://www.pharmaradar360.com/article/vktx-vs-bcrx-which-biotech-takeover-favorite-offers-more-upside-after-vertex-s-1-3f511bc74011a51fPharma Surgeen2026-07-08T05:14:31.000ZVKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?https://www.pharmaradar360.com/article/ono-pharmaceutical-tse-4528-could-be-33-undervalued-as-opdivo-and-pipeline-progr-546c5af262a6f57bPharma Surgeen2026-07-08T05:08:14.000ZOno Pharmaceutical (TSE:4528) Could Be 33% Undervalued As Opdivo And Pipeline Progress Buildhttps://www.pharmaradar360.com/article/aribio-nears-phase-3-results-for-oral-alzheimer-s-drug-mason-capital-s-investmen-db513a87f3646f6fPharma Surgeen2026-07-08T04:55:17.000ZAribio Nears Phase 3 Results for Oral Alzheimer’s Drug... Mason Capital’s Investment Performance Becomes Visiblehttps://www.pharmaradar360.com/article/bpc-157-not-fda-approved-the-u-s-food-and-drug-administration-is-moving-toward-a-a63624218fcfc954Pharma Surgeen2026-07-08T04:53:59.000Zbpc 157 not fda approved The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies ⁠to produce more than a dozen injectable peptides that were banned because of ⁠potentially significant safety risks, the New Yorkhttps://www.pharmaradar360.com/article/exposeiq-juryfit-helps-pharmaceutical-litigation-teams-transform-jury-selection-c907d646e69d1cfePharma Surgeen2026-07-08T04:24:13.000ZExposeIQ JuryFit Helps Pharmaceutical Litigation Teams Transform Jury Selection Strategy with Human-Verified Insightshttps://www.pharmaradar360.com/article/geared-power-biotech-ceo-gary-kellstrom-jr-featured-on-going-beyond-the-deal-pod-2c9efd48b0a5a176Pharma Surgeen2026-07-08T04:18:00.000ZGeared Power BioTech CEO, Gary Kellstrom, Jr. Featured on 'Going Beyond the Deal' Podcast with J. Michael Fischer, Jr.https://www.pharmaradar360.com/article/hc-questions-fda-push-to-invoke-mcoca-in-food-safety-cases-across-maha-fcb9e5bd41c90abcPharma Surgeen2026-07-08T03:43:08.000ZHC questions FDA push to invoke MCOCA in food safety cases across Mahahttps://www.pharmaradar360.com/article/three-pharmaceutical-stocks-to-consider-buying-to-profit-from-a-weight-loss-tren-b5783866e0fae922Pharma Surgeen2026-07-08T02:40:11.000ZThree Pharmaceutical Stocks to Consider Buying to Profit from a Weight-Loss Trendhttps://www.pharmaradar360.com/article/pangea-pharmaceuticals-advances-its-next-phase-of-growth-with-an-expanding-comme-6e83c8b200dcb713Pharma Surgeen2026-07-08T01:40:21.000ZPangea Pharmaceuticals Advances Its Next Phase of Growth With an Expanding Commercial Portfoliohttps://www.pharmaradar360.com/article/medipost-doses-first-patient-in-u-s-phase-3-trial-for-knee-osteoarthritis-cell-t-b60b100516ced2b9Pharma Surgeen2026-07-08T01:17:00.000ZMedipost Doses First Patient in U.S. Phase 3 Trial for Knee Osteoarthritis Cell Therapy 'Cartistem'https://www.pharmaradar360.com/article/medipost-s-cartistem-begins-u-s-phase-3-doses-first-patient-5570110fb340b198Pharma Surgeen2026-07-08T00:38:25.000ZMedipost's Cartistem Begins U.S. Phase 3, Doses First Patienthttps://www.pharmaradar360.com/article/moderna-filed-form-8-k-738819d8b969f9c5Pharma Surgeen2026-07-08T00:00:00.000ZModerna filed Form 8-Khttps://www.pharmaradar360.com/article/view-all-in-depth-f57711315ba4a48ePharma Surgeen2026-07-08T00:00:00.000ZView all in-depthhttps://www.pharmaradar360.com/article/novel-life-saving-liver-procedure-recommended-potentially-enabling-hundreds-more-fd16c74af776d6dcPharma Surgeen2026-07-08T00:00:00.000ZNovel life-saving liver procedure recommended, potentially enabling hundreds more transplantshttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-08T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-5bc0a73e5b42e5c9Pharma Surgeen2026-07-08T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-09bdc229ae55589aPharma Surgeen2026-07-08T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-23c742c1413e6e11Pharma Surgeen2026-07-08T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-1560d4e1d877f904Pharma Surgeen2026-07-08T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-5c30380fa91bc817Pharma Surgeen2026-07-08T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-a52c0766eb756ab2Pharma Surgeen2026-07-08T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-21a968c1afa6f5d2Pharma Surgeen2026-07-08T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-ec8bec6b45dad569Pharma Surgeen2026-07-08T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-e8ba05c60e7ca7d8Pharma Surgeen2026-07-08T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-0c4a79041fd9b089Pharma Surgeen2026-07-08T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-f76455af0e4a5724Pharma Surgeen2026-07-08T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-102990df460508fePharma Surgeen2026-07-08T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-d5b5fd388de2b5fbPharma Surgeen2026-07-08T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-0a45c5dd28ad1209Pharma Surgeen2026-07-08T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-tianeptine-in-schedule-i-b7e74286d39bdc0dPharma Surgeen2026-07-08T00:00:00.000ZSchedules of Controlled Substances: Placement of Tianeptine in Schedule Ihttps://www.pharmaradar360.com/article/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establis-f5269d09f9bc98a4Pharma Surgeen2026-07-08T00:00:00.000ZCellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvechttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-generic-clearance-for-the-collection-91294e50f67440a0Pharma Surgeen2026-07-08T00:00:00.000ZProposed Collection; 60-Day Comment Request: Generic Clearance for the Collection of Customer Participation and Performance Management With NIH Programs, Products, and Services (Office of the Director)https://www.pharmaradar360.com/article/government-owned-invention-available-for-license-method-of-detecting-circulating-2211f39fd3f4154ePharma Surgeen2026-07-08T00:00:00.000ZGovernment Owned Invention Available for License: Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereofhttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-generating-conditional-and-reve-8316d35061ffc105Pharma Surgeen2026-07-08T00:00:00.000ZGovernment Owned Invention Available for License: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2https://www.pharmaradar360.com/article/medicare-program-announcement-of-the-advisory-panel-on-hospital-outpatient-payme-5c1e6154f8d9d08cPharma Surgeen2026-07-08T00:00:00.000ZMedicare Program; Announcement of the Advisory Panel on Hospital Outpatient Payment Meeting-August 24, 2026https://www.pharmaradar360.com/article/medical-device-user-fee-amendments-public-meeting-request-for-comments-7a49cc926bbb6ad4Pharma Surgeen2026-07-08T00:00:00.000ZMedical Device User Fee Amendments; Public Meeting; Request for Commentshttps://www.pharmaradar360.com/article/aripiprazole-versus-bupropion-augmentation-in-patients-with-anxious-depression-r-cf3372bb7dd2b5f9Pharma Surgeen2026-07-08T00:00:00.000ZAripiprazole versus Bupropion Augmentation in Patients with Anxious Depression Resistant to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-label, Multicenter Studyhttps://www.pharmaradar360.com/article/hyaluronidase-in-aesthetic-plastic-surgery-clinical-uses-safety-ultrasound-guida-e51108891367ee49Pharma Surgeen2026-07-08T00:00:00.000ZHyaluronidase in Aesthetic Plastic Surgery: Clinical Uses, Safety, Ultrasound Guidance, And Current Controversieshttps://www.pharmaradar360.com/article/rothmund-thomson-syndrome-revisited-expanding-the-genotypic-spectrum-deciphering-79205d672374fe0bPharma Surgeen2026-07-08T00:00:00.000ZRothmund-Thomson Syndrome Revisited: Expanding the Genotypic Spectrum, Deciphering RECQL4-Related Pathomechanisms, And Redefining Long-Term Surveillance Strategies for An Underrecognized Genodermatosishttps://www.pharmaradar360.com/article/case-report-when-access-is-limited-using-cyp3a4-inhibition-to-maintain-clinical-f5d65d53f5048cdePharma Surgeen2026-07-08T00:00:00.000ZCase Report: When access is limited: using CYP3A4 inhibition to maintain clinical benefit from elexacaftor/tezacaftor/ivacaftorhttps://www.pharmaradar360.com/article/case-report-from-misdiagnosis-to-successful-treatment-using-mepolizumab-in-anca-1b61c157d8ed1a2cPharma Surgeen2026-07-08T00:00:00.000ZCase Report: From misdiagnosis to successful treatment using mepolizumab in ANCA-negative severe EGPA—clinical lessons in eosinophil-targeted therapyhttps://www.pharmaradar360.com/article/clinical-and-immunological-characterization-of-nfkb1-haploinsufficiency-in-japan-4144db110006ee40Pharma Surgeen2026-07-08T00:00:00.000ZClinical and immunological characterization of NFKB1 haploinsufficiency in Japanhttps://www.pharmaradar360.com/article/clinical-characteristics-and-risk-factors-of-atrial-fibrillation-detection-after-99fb4f834fbf47dfPharma Surgeen2026-07-08T00:00:00.000ZClinical characteristics and risk factors of atrial fibrillation detection after acute ischemic strokehttps://www.pharmaradar360.com/article/divergence-in-surface-protein-exposure-between-reference-and-clinical-derived-ca-371721d81f08e23cPharma Surgeen2026-07-08T00:00:00.000ZDivergence in surface protein exposure between reference and clinical-derived Candida glabrata (Nakaseomyces glabratus) strains (CBS138 vs. BG2) – a preliminary proteomic perspectivehttps://www.pharmaradar360.com/article/effects-of-breaking-up-prolonged-sitting-with-an-office-based-exercise-program-o-247f4c2f20cc7684Pharma Surgeen2026-07-08T00:00:00.000ZEffects of Breaking Up Prolonged Sitting with an Office-Based Exercise Program on Sitting Time, Physical Activity, Musculoskeletal Discomfort, and Stress in Office Workers: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/the-gut-microbiome-tumor-microenvironment-axis-in-immunotherapy-response-mechani-93920ee5011ed1c6Pharma Surgeen2026-07-08T00:00:00.000ZThe gut microbiome–tumor microenvironment axis in immunotherapy response: Mechanistic insights and clinical implicationshttps://www.pharmaradar360.com/article/an-evidence-based-cognitive-stimulation-and-physical-activity-intervention-to-de-276415f7a6028a13Pharma Surgeen2026-07-08T00:00:00.000ZAn Evidence-Based Cognitive Stimulation and Physical Activity Intervention to Delay Aging-Related Decline: Protocol for a Randomized Controlled Trialhttps://www.pharmaradar360.com/article/in-vivo-evaluations-of-drug-delivery-to-the-brain-e04904ce244e216bPharma Surgeen2026-07-08T00:00:00.000ZIn Vivo Evaluations of Drug Delivery to the Brainhttps://www.pharmaradar360.com/article/exosomes-for-drug-delivery-to-the-brain-d3554e43480613bePharma Surgeen2026-07-08T00:00:00.000ZExosomes for Drug Delivery to the Brainhttps://www.pharmaradar360.com/article/association-between-the-zju-index-and-clinical-outcomes-in-patients-with-acute-m-78de92bbd1b47020Pharma Surgeen2026-07-08T00:00:00.000ZAssociation between the ZJU Index and clinical outcomes in patients with acute myocardial infarctionhttps://www.pharmaradar360.com/article/artificial-intelligence-in-shoulder-arthroplasty-latest-concepts-and-clinical-in-438ad71706a474c1Pharma Surgeen2026-07-08T00:00:00.000ZArtificial intelligence in shoulder arthroplasty: latest concepts and clinical integrationhttps://www.pharmaradar360.com/article/clinical-rationale-for-thymic-restoration-in-adult-immunosenescence-88ba1878e1e781c2Pharma Surgeen2026-07-08T00:00:00.000ZClinical rationale for thymic restoration in adult immunosenescencehttps://www.pharmaradar360.com/article/dental-students-perceptions-of-preclinical-and-clinical-prosthodontic-education-0578482fe8a87a01Pharma Surgeen2026-07-08T00:00:00.000ZDental students’ perceptions of preclinical and clinical prosthodontic education: a cross-sectional surveyhttps://www.pharmaradar360.com/article/the-effect-of-foraminal-enlargement-and-irrigant-activation-technique-on-post-op-591d225bece4520fPharma Surgeen2026-07-08T00:00:00.000ZThe effect of foraminal enlargement and irrigant activation technique on post-operative pain in necrotic teeth - a clinical studyhttps://www.pharmaradar360.com/article/clinical-characteristics-and-risk-factors-for-mortality-in-pulmonary-mucormycosi-7fc5c0144ba5ef8bPharma Surgeen2026-07-08T00:00:00.000ZClinical characteristics and risk factors for mortality in pulmonary mucormycosis among patients with non-hematologic malignancieshttps://www.pharmaradar360.com/article/continuous-adductor-canal-block-versus-continuous-femoral-nerve-block-for-analge-2c2bb04f6c38d030Pharma Surgeen2026-07-08T00:00:00.000ZContinuous adductor canal block versus continuous femoral nerve block for analgesia after open reduction and internal fixation of patellar fractures: a randomized controlled trialhttps://www.pharmaradar360.com/article/incidence-and-clinical-characteristics-of-taxane-induced-peripheral-neuropathy-r-f8e55a8f9f0cd0daPharma Surgeen2026-07-08T00:00:00.000ZIncidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancerhttps://www.pharmaradar360.com/article/clinical-triage-of-individuals-with-warning-symptoms-of-imminent-cardiac-arrest-58e558e190cb4c96Pharma Surgeen2026-07-08T00:00:00.000ZClinical Triage of Individuals With Warning Symptoms of Imminent Cardiac Arresthttps://www.pharmaradar360.com/article/av-node-ablation-and-conduction-system-pacing-versus-biventricular-pacing-in-pat-f838622e8543347aPharma Surgeen2026-07-08T00:00:00.000ZAV Node Ablation and Conduction System Pacing Versus Biventricular Pacing in Patients With AF and HFhttps://www.pharmaradar360.com/article/right-aortic-arch-and-double-arch-current-clinical-challenges-9ec936663d703351Pharma Surgeen2026-07-08T00:00:00.000ZRight aortic arch and double arch: current clinical challengeshttps://www.pharmaradar360.com/article/a-point-prevalence-survey-on-antibiotic-dispensing-practices-identifies-targets-0fe0ccc8d4f76306Pharma Surgeen2026-07-08T00:00:00.000ZA point prevalence survey on antibiotic dispensing practices identifies targets for quality improvement of antimicrobial stewardship in community pharmacies in Dar es Salaam, Tanzaniahttps://www.pharmaradar360.com/article/therapeutic-use-of-cardioselective-beta-blockers-for-patients-with-chronic-obstr-b5b664640af1ead9Pharma Surgeen2026-07-08T00:00:00.000ZTherapeutic use of cardioselective beta-blockers for patients with chronic obstructive pulmonary disease: a review of current clinical evidencehttps://www.pharmaradar360.com/article/multilevel-brain-heart-interaction-correlates-with-suicidal-ideation-in-first-ep-87953b4158e8dcdfPharma Surgeen2026-07-08T00:00:00.000ZMultilevel brain heart interaction correlates with suicidal ideation in first episode drug naive major depressive disorderhttps://www.pharmaradar360.com/article/fda-approves-novel-cell-therapy-made-with-haematopoietic-stem-cells-tregs-and-t-bf0b6424128c3206Pharma Surgeen2026-07-08T00:00:00.000ZFDA approves novel cell therapy made with haematopoietic stem cells, Tregs and T cellshttps://www.pharmaradar360.com/article/car-t-cell-therapy-for-solid-cancer-scores-first-approval-in-china-de2524c2440e8451Pharma Surgeen2026-07-08T00:00:00.000ZCAR T cell therapy for solid cancer scores first approval in Chinahttps://www.pharmaradar360.com/article/killing-the-messiah-the-trial-and-crucifixion-of-jesus-of-nazareth-by-nathaniel-aafd4264d4178228Pharma Surgeen2026-07-08T00:00:00.000ZKilling the Messiah: The Trial and Crucifixion of Jesus of Nazareth By Nathaniel J. Andrade, Oxford: Oxford University Press, 2025. 273 pp.https://www.pharmaradar360.com/article/the-costs-of-partner-engagement-in-research-opportunities-for-pragmatic-research-a34f36841467805cPharma Surgeen2026-07-08T00:00:00.000ZThe Costs of Partner Engagement in Research: Opportunities for Pragmatic Research, Implementation Science, and the Science of Engagementhttps://www.pharmaradar360.com/article/exploring-the-mechanism-by-which-triphenyl-phosphate-promotes-malignant-phenotyp-72da33fbc150b22fPharma Surgeen2026-07-08T00:00:00.000ZExploring the mechanism by which triphenyl phosphate promotes malignant phenotypes in bladder and kidney cancer through MMP9 based on bioinformatics analysis and experimental validationhttps://www.pharmaradar360.com/article/low-dose-not-low-risk-potential-adrenal-suppression-identified-by-a-risk-based-a-810a5cdc0a3d5075Pharma Surgeen2026-07-08T00:00:00.000ZLow-dose, not low-risk: potential adrenal suppression identified by a risk-based approach to ACTH testinghttps://www.pharmaradar360.com/article/effects-of-exercise-on-physical-function-and-pain-in-adults-with-rheumatoid-arth-1b71d2532497a0a6Pharma Surgeen2026-07-08T00:00:00.000ZEffects of exercise on physical function and pain in adults with rheumatoid arthritis: an exit meta-analysis of randomized controlled trialshttps://www.pharmaradar360.com/article/towards-multidisciplinary-summarization-of-hospital-stays-efficient-sentence-lev-d591ebb85f9cd97aPharma Surgeen2026-07-08T00:00:00.000ZTowards Multidisciplinary Summarization of Hospital Stays: Efficient Sentence-Level Clinical Section Categorizationhttps://www.pharmaradar360.com/article/machine-learning-for-early-prediction-of-gestational-diabetes-mellitus-using-rou-a41f7c63f42f9b7fPharma Surgeen2026-07-08T00:00:00.000ZMachine Learning for Early Prediction of Gestational Diabetes Mellitus Using Routinely Collected Clinical Datahttps://www.pharmaradar360.com/article/ontology-aligned-clinical-ner-in-emergency-medicine-using-weak-supervision-74e1bdbd9f416fa0Pharma Surgeen2026-07-08T00:00:00.000ZOntology-Aligned Clinical NER in Emergency Medicine Using Weak Supervisionhttps://www.pharmaradar360.com/article/reasoning-enhanced-rare-event-prediction-with-balanced-outcome-correction-for-cl-2a90ce6b58b634ddPharma Surgeen2026-07-08T00:00:00.000ZReasoning-Enhanced Rare-Event Prediction with Balanced Outcome Correction for Clinical Decision Supporthttps://www.pharmaradar360.com/article/transforming-hospitals-with-artificial-intelligence-applications-in-clinical-edu-a5b87ec1a8845c51Pharma Surgeen2026-07-08T00:00:00.000ZTransforming Hospitals with Artificial Intelligence: Applications in Clinical Education and Patient Carehttps://www.pharmaradar360.com/article/bone-stability-after-regenerative-peri-implantitis-treatment-a-10-year-follow-up-86841b38e9ab986cPharma Surgeen2026-07-08T00:00:00.000ZBone stability after regenerative peri‐implantitis treatment: A 10‐year follow‐up case studyhttps://www.pharmaradar360.com/article/medipost-starts-us-phase-3-trial-of-cartistem-to-expand-from-korea-chosunbiz-06da76e67cb13a3cPharma Surgeen2026-07-07T23:54:00.000ZMedipost starts US phase 3 trial of Cartistem to expand from Korea - CHOSUNBIZhttps://www.pharmaradar360.com/article/podcast-servier-describes-its-m-a-and-manufacturing-strategy-amidst-deal-making-0cbe957599ce520cPharma Surgeen2026-07-07T23:09:29.000ZPodcast: Servier describes its M&A and manufacturing strategy amidst deal-making drivehttps://www.pharmaradar360.com/article/10-year-capital-plan-to-rebuild-nhs-and-bring-care-closer-to-home-e41690781bc7de8bPharma Surgeen2026-07-07T23:05:04.000Z10 Year Capital Plan to rebuild NHS and bring care closer to homehttps://www.pharmaradar360.com/article/nextgen-vc-podcast-why-the-future-of-biotech-starts-with-the-brain-f52960dd9f0c3e44Pharma Surgeen2026-07-07T22:31:03.000ZNextGen VC Podcast – Why the Future of Biotech Starts with the Brainhttps://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-e2f912a2cb1e14dePharma Surgeen2026-07-07T22:13:06.000ZCMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filinghttps://www.pharmaradar360.com/article/june-6-2026-judge-blocks-colorado-price-cap-on-enbrel-33e0da6279a0c4d3Pharma Surgeen2026-07-07T21:26:28.000ZJune 6, 2026: Judge blocks Colorado price cap on Enbrelhttps://www.pharmaradar360.com/article/panel-reviews-food-adulteration-cases-406e980fb606225ePharma Surgeen2026-07-07T20:57:57.000ZPanel reviews food adulteration caseshttps://www.pharmaradar360.com/article/first-in-class-drug-approved-for-iga-nephropathy-a36d8e95ed297e40Pharma Surgeen2026-07-07T20:52:59.000ZFirst-in-Class Drug Approved for IgA Nephropathyhttps://www.pharmaradar360.com/article/3-reasons-to-buy-novo-nordisk-stock-6a25836f53ed473fPharma Surgeen2026-07-07T20:36:47.000Z3 Reasons to Buy Novo Nordisk Stockhttps://www.pharmaradar360.com/article/industry-groups-press-fda-for-transparency-next-steps-for-cnpv-program-4fc0d261d56b9066Pharma Surgeen2026-07-07T20:19:00.000ZIndustry groups press FDA for transparency, next steps for CNPV programhttps://www.pharmaradar360.com/article/obesity-biotech-kalohexis-confidentially-files-to-go-public-in-us-e785e6640d67808bPharma Surgeen2026-07-07T19:59:53.000ZObesity biotech Kalohexis confidentially files to go public in UShttps://www.pharmaradar360.com/article/coregen-clears-fda-hurdle-to-start-clinical-trials-for-cancer-therapy-this-fall-b268bd4cdf6334ffPharma Surgeen2026-07-07T19:55:00.000ZCoRegen clears FDA hurdle to start clinical trials for cancer therapy this fallhttps://www.pharmaradar360.com/article/the-changing-reality-of-pharmaceutical-commercialization-pharmexec-4fe54bfc12361d4ePharma Surgeen2026-07-07T19:25:29.000ZThe Changing Reality of Pharmaceutical Commercialization | PharmExechttps://www.pharmaradar360.com/article/this-space-bound-biotech-startup-thinks-it-can-cure-cognitive-decline-and-it-jus-0cb529ccd1063bb1Pharma Surgeen2026-07-07T19:22:36.000ZThis Space-Bound Biotech Startup Thinks It Can Cure Cognitive Decline—and It Just Launched a Historic Experimenthttps://www.pharmaradar360.com/article/bedford-approves-tax-incentive-to-bring-300-plus-pharmaceutical-jobs-to-city-e0dd926cef835edePharma Surgeen2026-07-07T19:18:00.000ZBedford approves tax incentive to bring 300-plus pharmaceutical jobs to cityhttps://www.pharmaradar360.com/article/cose-dean-carmen-domingo-honored-for-fostering-next-generation-of-biotech-talent-010ad06419846903Pharma Surgeen2026-07-07T18:56:07.000ZCoSE Dean Carmen Domingo honored for fostering next generation of biotech talenthttps://www.pharmaradar360.com/article/this-biotech-stock-is-soaring-99-after-vertex-agrees-to-takeover-deal-f2b00cb4fc552de5Pharma Surgeen2026-07-07T18:41:00.000ZThis Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Dealhttps://www.pharmaradar360.com/article/biotech-and-biomed-engineering-grad-and-certificate-programs-to-debut-at-auburn-a7b6667639a44061Pharma Surgeen2026-07-07T18:00:24.000ZBiotech and Biomed Engineering Grad and Certificate Programs to Debut at Auburnhttps://www.pharmaradar360.com/article/axsome-therapeutics-doses-first-pediatric-patient-in-phase-3-adhd-study-c018ab6b063d9acdPharma Surgeen2026-07-07T17:41:00.000ZAxsome Therapeutics doses first pediatric patient in Phase 3 ADHD studyhttps://www.pharmaradar360.com/article/dea-scientist-testifies-against-dea-s-own-rescheduling-posture-in-court-238ba9f6d7a592bePharma Surgeen2026-07-07T17:35:00.000ZDEA Scientist Testifies Against DEA's Own Rescheduling Posture In Courthttps://www.pharmaradar360.com/article/online-glp-1-prescribing-lacks-adequate-safety-oversight-a219cf1c456f91eaPharma Surgeen2026-07-07T16:53:22.000ZOnline GLP-1 Prescribing Lacks Adequate Safety, Oversighthttps://www.pharmaradar360.com/article/merck-kgaa-backed-cyllene-therapeutics-secures-33m-for-gene-therapy-pipeline-fe3b4765de0b2965Pharma Surgeen2026-07-07T16:35:50.000ZMerck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipelinehttps://www.pharmaradar360.com/article/sls-stock-sellas-investors-look-for-more-after-542-surge-e44ea3f5331d8efaPharma Surgeen2026-07-07T16:32:12.000ZSLS Stock: SELLAS Investors Look For More After 542% Surgehttps://www.pharmaradar360.com/article/jim-cramer-calls-biotech-the-hottest-group-in-the-market-as-he-predicts-deals-ar-b7734cea981d3088Pharma Surgeen2026-07-07T16:30:17.000ZJim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”https://www.pharmaradar360.com/article/jim-cramer-calls-biotech-the-hottest-group-in-the-market-as-he-predicts-deals-ar-bb158b1232959531Pharma Surgeen2026-07-07T16:30:17.000ZJim Cramer Calls Biotech "The Hottest Group in the Market" as He Predicts "Deals Are Going to Be Flooding the Market"https://www.pharmaradar360.com/article/fda-approves-vera-s-dual-target-trutakna-setting-up-igan-market-battle-with-nova-d2af769a83af6343Pharma Surgeen2026-07-07T16:23:07.000ZFDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsukahttps://www.pharmaradar360.com/article/study-identifies-tiered-manufacturing-across-global-pharmaceutical-markets-as-po-b4b47357fb8fa145Pharma Surgeen2026-07-07T16:09:04.000ZStudy Identifies “Tiered Manufacturing” Across Global Pharmaceutical Markets as Potential Determinant of Healthhttps://www.pharmaradar360.com/article/fda-advisory-panel-to-assess-peptide-bulk-drug-substances-from-obesity-to-opioid-5c21d5c320866f96Pharma Surgeen2026-07-07T16:08:22.000ZFDA Advisory Panel to Assess Peptide Bulk Drug Substances from Obesity to Opioidhttps://www.pharmaradar360.com/article/this-small-cap-biotech-is-turning-heads-on-wall-street-52783d3ebae9a9afPharma Surgeen2026-07-07T16:05:00.000ZThis Small-Cap Biotech Is Turning Heads on Wall Streethttps://www.pharmaradar360.com/article/kailera-says-obesity-pill-succeeds-in-late-stage-trial-in-china-f631dadf9197a253Pharma Surgeen2026-07-07T16:03:02.000ZKailera says obesity pill succeeds in late-stage trial in Chinahttps://www.pharmaradar360.com/article/fda-s-regulatory-outlook-897a255287271b38Pharma Surgeen2026-07-07T16:00:00.000ZFDA’s regulatory outlookhttps://www.pharmaradar360.com/article/biotech-supply-chain-market-size-share-growth-report-2034-0bf1acaaa5e8abc0Pharma Surgeen2026-07-07T15:41:40.000ZBiotech Supply Chain Market Size, Share | Growth Report [2034]https://www.pharmaradar360.com/article/novartis-to-acquire-adc-biotech-myricx-bio-for-1-5bn-56b40655fcd95954Pharma Surgeen2026-07-07T15:41:30.000ZNovartis to acquire ADC biotech Myricx Bio for $1.5bnhttps://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-shareholders-should-watch-novartis-latest-1-5b-adc-ac-7536759cd5510347Pharma Surgeen2026-07-07T15:35:31.000ZVERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisitionhttps://www.pharmaradar360.com/article/astrazeneca-developing-pp-blister-packaging-for-future-drugs-d700989ebf81edf4Pharma Surgeen2026-07-07T15:26:00.000ZAstraZeneca developing PP blister packaging for future drugshttps://www.pharmaradar360.com/article/cordis-project-engineered-cartilage-from-nose-for-the-treatment-of-osteoarthriti-382e41fbb850d474Pharma Surgeen2026-07-07T15:21:15.000ZCORDIS project: ENgineered CArtilage from Nose for the Treatment of Osteoarthritis (ENCANTO)https://www.pharmaradar360.com/article/compass-says-depression-drug-has-long-lasting-benefits-2047ae6c03ce0bccPharma Surgeen2026-07-07T15:06:16.000ZCompass says depression drug has long-lasting benefitshttps://www.pharmaradar360.com/article/peptide-exceptionalism-is-a-dangerous-fda-loophole-demand-evidence-not-hype-919d4a33842b47c2Pharma Surgeen2026-07-07T15:00:00.000ZPeptide exceptionalism is a dangerous FDA loophole. Demand evidence, not hypehttps://www.pharmaradar360.com/article/boehringer-bags-pvt-s-viral-vector-platform-for-cancer-vaccine-r-d-ad7dd9fe82d08aadPharma Surgeen2026-07-07T14:35:39.000ZBoehringer bags PVT’s viral vector platform for cancer vaccine R&Dhttps://www.pharmaradar360.com/article/update-class-4-medicines-defect-notification-relonchem-limited-gabapentin-relonc-c6f77c17ff41d38ePharma Surgeen2026-07-07T14:34:28.000ZUPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31https://www.pharmaradar360.com/article/as-us-lawmakers-increase-scrutiny-of-chinese-trials-industry-fears-huge-distract-31315b744926797aPharma Surgeen2026-07-07T14:30:00.000ZAs US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’https://www.pharmaradar360.com/article/package-deals-in-the-pharmaceutical-industry-and-disclosure-uk-data-a5353555b90b69abPharma Surgeen2026-07-07T14:28:38.000ZPackage deals in the pharmaceutical industry and Disclosure UK datahttps://www.pharmaradar360.com/article/disclosure-uk-2025-the-11th-year-of-disclosure-uk-data-with-industry-transparenc-0963ee0ff7faa284Pharma Surgeen2026-07-07T14:28:38.000ZDisclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to growhttps://www.pharmaradar360.com/article/updates-to-the-nhs-commercial-framework-must-deliver-more-flexibility-to-support-b8379101aa8a50adPharma Surgeen2026-07-07T14:28:38.000ZUpdates to the NHS Commercial Framework must deliver more flexibility to support timely access to medicineshttps://www.pharmaradar360.com/article/greater-ambition-is-needed-to-improve-patient-access-to-innovative-medicines-48edf83374fee6f2Pharma Surgeen2026-07-07T14:28:37.000ZGreater ambition is needed to improve patient access to innovative medicineshttps://www.pharmaradar360.com/article/sbio-biotech-breakthrough-opportunities-screened-for-cash-burn-nysearca-sbio-173668196e352df4Pharma Surgeen2026-07-07T14:28:30.000ZSBIO: Biotech Breakthrough Opportunities Screened For Cash Burn (NYSEARCA:SBIO)https://www.pharmaradar360.com/article/endevica-spinout-kalohexis-submits-confidential-ipo-filing-to-develop-obesity-ch-03945869493ac098Pharma Surgeen2026-07-07T14:21:06.000ZEndevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1shttps://www.pharmaradar360.com/article/celea-therapeutics-lands-180-million-to-launch-first-head-to-gead-phase-3-ipf-tr-b5d8666ccf06687aPharma Surgeen2026-07-07T14:14:43.000ZCelea Therapeutics lands $180 million to launch first head-to-gead Phase 3 IPF trialhttps://www.pharmaradar360.com/article/new-heart-disease-and-strokes-plan-to-saves-thousands-of-lives-c27dc18b349b6a5aPharma Surgeen2026-07-07T14:08:23.000ZNew heart disease and strokes plan to saves thousands of liveshttps://www.pharmaradar360.com/article/sls-stock-sellas-investors-look-for-more-after-542-surge-2191fe70ced66c70Pharma Surgeen2026-07-07T14:06:10.000ZSLS Stock: SELLAS Investors Look For More After 542% Surgehttps://www.pharmaradar360.com/article/sen-rick-scott-wants-pharmaceutical-tariff-carve-out-reversed-over-china-s-force-961f5d031ac8c9f0Pharma Surgeen2026-07-07T14:03:19.000ZSen. Rick Scott wants pharmaceutical tariff carve-out reversed over China’s forced laborhttps://www.pharmaradar360.com/article/press-release-biocartis-nv-biocartis-and-discovery-life-sciences-announce-strate-8e639da711c6b5a3Pharma Surgeen2026-07-07T14:00:13.000ZPress Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnosticshttps://www.pharmaradar360.com/article/obesity-biotech-kalohexis-files-confidential-ipo-c8afc87a0fc6946fPharma Surgeen2026-07-07T13:49:32.000ZObesity biotech Kalohexis files confidential IPOhttps://www.pharmaradar360.com/article/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-trea-6588f1bb9498345cPharma Surgeen2026-07-07T13:40:26.000ZSaol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Diseasehttps://www.pharmaradar360.com/article/world-retinoic-acid-market-analysis-forecast-size-trends-and-insights-8fb7ea9a9fe3288bPharma Surgeen2026-07-07T13:31:09.000ZWorld Retinoic Acid - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/cardiovascular-disease-modern-service-framework-691b4f1d262fd8caPharma Surgeen2026-07-07T13:28:10.000ZCardiovascular disease modern service frameworkhttps://www.pharmaradar360.com/article/technical-annex-cardiovascular-disease-modern-service-framework-1df86f822117b46aPharma Surgeen2026-07-07T13:28:06.000ZTechnical annex: cardiovascular disease modern service frameworkhttps://www.pharmaradar360.com/article/cardiovascular-disease-modern-service-framework-30f876a4a0b105a9Pharma Surgeen2026-07-07T13:28:00.000ZCardiovascular disease modern service frameworkhttps://www.pharmaradar360.com/article/crinetics-pharmaceuticals-acquired-by-fortress-biotech-for-10-b-bce72cb70d9e8564Pharma Surgeen2026-07-07T13:24:16.000ZCrinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Bhttps://www.pharmaradar360.com/article/em-nota-entidades-do-setor-farmaceutico-alertam-para-riscos-de-produtos-sem-regi-2404c45feca06133Pharma Surgeen2026-07-07T13:16:52.000ZEm nota, entidades do setor farmacêutico alertam para riscos de produtos sem registro no Brasilhttps://www.pharmaradar360.com/article/novo-nordisk-signs-agreement-with-biotech-company-to-evaluate-semaglutide-implan-43badcf6c13842b8Pharma Surgeen2026-07-07T13:15:00.000ZNovo Nordisk signs agreement with biotech company to evaluate semaglutide implanthttps://www.pharmaradar360.com/article/purely-golden-foods-brings-biopharma-rigor-to-pet-nutrition-bizwomen-b2fbda198664da52Pharma Surgeen2026-07-07T12:58:00.000ZPurely Golden Foods brings biopharma rigor to pet nutrition - Bizwomenhttps://www.pharmaradar360.com/article/former-vertex-gsk-exec-launches-science-first-pet-nutrition-company-2059dd18016c2f89Pharma Surgeen2026-07-07T12:58:00.000ZFormer Vertex, GSK exec launches science-first pet nutrition companyhttps://www.pharmaradar360.com/article/obesity-biotech-kalohexis-confidentially-files-to-go-public-in-us-e8716115709af6bdPharma Surgeen2026-07-07T12:47:49.000ZObesity biotech Kalohexis confidentially files to go public in UShttps://www.pharmaradar360.com/article/nice-recommends-endosure-and-endotest-diagnostics-for-endometriosis-e31e9006a8a86152Pharma Surgeen2026-07-07T12:35:00.000ZNICE recommends Endosure and Endotest diagnostics for endometriosishttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-bioray-biotech-co-ltd-tpex-7561-b336d708c238a025Pharma Surgeen2026-07-07T12:32:00.000ZEnterprise value to EBITDA forward of Bioray Biotech Co., Ltd – TPEX:7561https://www.pharmaradar360.com/article/de-risking-drug-formulation-with-ai-predictive-modelling-025dba969a2c8323Pharma Surgeen2026-07-07T12:26:34.000ZDe-risking drug formulation with AI predictive modellinghttps://www.pharmaradar360.com/article/kymera-hires-ex-sanofi-executive-to-lead-kt-621-development-9b065a4bbbf31f2fPharma Surgeen2026-07-07T12:17:50.000ZKymera hires ex-Sanofi executive to lead KT-621 developmenthttps://www.pharmaradar360.com/article/toekomstige-europese-wetgevingen-stand-van-zaken-ff29693ca5d85483Pharma Surgeen2026-07-07T12:14:28.000ZToekomstige Europese wetgevingen: stand van zakenhttps://www.pharmaradar360.com/article/the-role-of-standards-in-the-drug-supply-chain-cd8789cc8512c491Pharma Surgeen2026-07-07T12:08:16.000ZThe Role of Standards in the Drug Supply Chainhttps://www.pharmaradar360.com/article/absentia-labs-digital-liver-model-becomes-first-ai-drug-development-tool-accepte-091754fac1473261Pharma Surgeen2026-07-07T12:06:00.000ZAbsentia Labs' Digital Liver Model Becomes First AI Drug Development Tool Accepted Into FDA Qualification Programhttps://www.pharmaradar360.com/article/therivatm-biologics-announces-regulatory-authorization-to-proceed-with-a-virage2-f63e4edb44ad899cPharma Surgeen2026-07-07T12:04:54.000ZTheriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinomahttps://www.pharmaradar360.com/article/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-tr-6af8b55a83feb474Pharma Surgeen2026-07-07T12:04:17.000ZSpur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-io-biotech-inc-otc-iobtq-8dc91180ec7e42f2Pharma Surgeen2026-07-07T12:00:02.000ZEnterprise value to revenue forward of IO Biotech, Inc. – OTC:IOBTQhttps://www.pharmaradar360.com/article/tavneos-avacopan-and-health-canada-s-review-of-data-integrity-concerns-8bc4d1504481839fPharma Surgeen2026-07-07T12:00:00.000ZTAVNEOS (avacopan) and Health Canada’s Review of Data Integrity Concernshttps://www.pharmaradar360.com/article/theriva-wins-spain-nod-for-more-frequent-vcn-01-dosing-in-pancreatic-cancer-tria-f1106efacf0a71e9Pharma Surgeen2026-07-07T12:00:00.000ZTheriva wins Spain nod for more frequent VCN-01 dosing in pancreatic cancer trialhttps://www.pharmaradar360.com/article/vivani-medical-enters-into-agreement-with-novo-nordisk-to-evaluate-npm-139-a-min-70d84d711f698d62Pharma Surgeen2026-07-07T11:35:00.000ZVivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Managementhttps://www.pharmaradar360.com/article/dear-doctor-is-it-true-pharmaceutical-companies-are-suppressing-peptides-because-dc224bc8bee92912Pharma Surgeen2026-07-07T11:30:00.000ZDear Doctor: Is it true pharmaceutical companies are suppressing peptides because of competition?https://www.pharmaradar360.com/article/oculgen-enrolls-first-us-patient-in-global-phase-2-3-wet-amd-trial-ba09ef00dc882a3dPharma Surgeen2026-07-07T11:28:17.000ZOculgen enrolls first US patient in global phase 2/3 wet AMD trialhttps://www.pharmaradar360.com/article/incorporacion-al-mercosur-del-nuevo-reglamento-tecnico-para-la-leche-uat-ultra-a-17e1443c74066bdaPharma Surgeen2026-07-07T11:24:45.000ZIncorporación al MERCOSUR del nuevo Reglamento Técnico para la leche UAT (Ultra Alta Temperatura - UHT)https://www.pharmaradar360.com/article/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-pha-d4d8573a2400172bPharma Surgeen2026-07-07T11:22:31.000ZKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535https://www.pharmaradar360.com/article/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-a25ac20f1d365251Pharma Surgeen2026-07-07T11:22:21.000ZAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Diseasehttps://www.pharmaradar360.com/article/axsome-therapeutics-initiates-focus-2-phase-3-trial-of-solriamfetol-in-children-0840e43a096faefePharma Surgeen2026-07-07T11:22:08.000ZAxsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)https://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-6a4a3cae17e5d82cPharma Surgeen2026-07-07T11:15:03.000ZCMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filinghttps://www.pharmaradar360.com/article/field-safety-notices-29-june-to-03-july-2026-f51c6e309cfc832ePharma Surgeen2026-07-07T11:14:05.000ZField Safety Notices: 29 June to 03 July 2026https://www.pharmaradar360.com/article/what-do-i-need-to-know-about-daraxonrasib-the-new-treatment-for-pancreatic-cance-6b36c4a5afd43e73Pharma Surgeen2026-07-07T11:09:30.000ZWhat do I need to know about daraxonrasib, the new treatment for pancreatic cancer?https://www.pharmaradar360.com/article/fda-backs-single-phase-3-trial-for-alterity-s-msa-drug-ath434-5f6f015a20e0b674Pharma Surgeen2026-07-07T11:05:00.000ZFDA backs single Phase 3 trial for Alterity’s MSA drug ATH434https://www.pharmaradar360.com/article/axsome-starts-phase-3-adhd-trial-in-children-enrolling-468-patients-6a6061d761fd5388Pharma Surgeen2026-07-07T11:00:00.000ZAxsome starts Phase 3 ADHD trial in children, enrolling 468 patientshttps://www.pharmaradar360.com/article/kailera-s-oral-glp-1-pill-posted-11-1-weight-loss-in-phase-3-4f42bbdb11f8b3efPharma Surgeen2026-07-07T11:00:00.000ZKailera's oral GLP-1 pill posted 11.1% weight loss in Phase 3https://www.pharmaradar360.com/article/annovis-enrolls-850-patients-in-phase-3-alzheimer-s-study-0771ac8bbf58adc0Pharma Surgeen2026-07-07T11:00:00.000ZAnnovis enrolls 850 patients in Phase 3 Alzheimer’s studyhttps://www.pharmaradar360.com/article/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-pha-47f47641776a4e99Pharma Surgeen2026-07-07T11:00:00.000ZKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535https://www.pharmaradar360.com/article/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-66d4f99c8ab8984aPharma Surgeen2026-07-07T11:00:00.000ZAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Diseasehttps://www.pharmaradar360.com/article/dhsc-spending-over-25-000-12432027a49613e7Pharma Surgeen2026-07-07T10:58:45.000ZDHSC spending over £25,000https://www.pharmaradar360.com/article/shanghai-hong-kong-bootcamp-selects-ai-and-biotech-projects-3f642eeea2ab252dPharma Surgeen2026-07-07T10:58:43.000ZShanghai-Hong Kong Bootcamp Selects AI and Biotech Projectshttps://www.pharmaradar360.com/article/dhsc-spending-over-25-000-february-2026-b20ca4cb325bef21Pharma Surgeen2026-07-07T10:58:06.000ZDHSC: spending over £25,000, February 2026https://www.pharmaradar360.com/article/brandon-capital-scores-its-biggest-return-ever-with-2-1bn-biotech-acquisition-426c1053b54c6ee8Pharma Surgeen2026-07-07T10:34:17.000ZBrandon Capital scores its biggest return ever with $2.1bn biotech acquisitionhttps://www.pharmaradar360.com/article/rcs-intnl-biotechnology-portfolio-company-crinetics-acquired-by-vertex-3607d0b29e43fdcdPharma Surgeen2026-07-07T10:34:02.000ZRCS - Intnl. Biotechnology - Portfolio company Crinetics acquired by Vertexhttps://www.pharmaradar360.com/article/decision-advertising-investigations-june-2026-a316cedf64c3ced3Pharma Surgeen2026-07-07T10:30:42.000ZDecision: Advertising investigations: June 2026https://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-1895e594079472ebPharma Surgeen2026-07-07T10:30:12.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/compass-pathways-says-second-psilocybin-trial-kept-depression-benefit-for-6-mont-6b2f2d329a20da71Pharma Surgeen2026-07-07T10:30:00.000ZCompass Pathways says second psilocybin trial kept depression benefit for 6 monthshttps://www.pharmaradar360.com/article/compass-pathways-announces-six-month-data-from-second-phase-3-trial-confirming-r-273b8261b66b5a2dPharma Surgeen2026-07-07T10:30:00.000ZCompass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profilehttps://www.pharmaradar360.com/article/the-changing-reality-of-pharmaceutical-commercialization-in-a-cold-chain-driven-bb4990ff8d52755dPharma Surgeen2026-07-07T10:10:16.000ZThe Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Markethttps://www.pharmaradar360.com/article/ono-pharmaceutical-co-ophlf-moves-10-4-higher-will-this-strength-last-1598343eed217249Pharma Surgeen2026-07-07T10:08:00.000ZOno Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?https://www.pharmaradar360.com/article/cmg-pharmaceutical-co-ltd-announced-that-it-has-received-krw-45-billion-in-fundi-8762af8d7552bd85Pharma Surgeen2026-07-07T10:05:40.000ZCMG Pharmaceutical Co., Ltd. announced that it has received KRW 45 billion in funding from Korea Investment & Securities Co., Ltd.https://www.pharmaradar360.com/article/fda-outlines-single-phase-3-trial-plan-for-alterity-nasdaq-athe-ath434-e22cfc4168b03803Pharma Surgeen2026-07-07T10:04:06.000ZFDA outlines single Phase 3 trial plan for Alterity (NASDAQ: ATHE) ATH434https://www.pharmaradar360.com/article/uk-biotechs-struggling-to-access-finance-as-scale-up-concerns-grow-f52d1d5556bb95f0Pharma Surgeen2026-07-07T10:00:48.000ZUK biotechs struggling to access finance as scale-up concerns growhttps://www.pharmaradar360.com/article/west-to-host-second-quarter-2026-conference-call-c1f1a3d6d5ebf729Pharma Surgeen2026-07-07T10:00:00.000ZWest to Host Second-Quarter 2026 Conference Callhttps://www.pharmaradar360.com/article/why-maharashtra-fda-banned-compulsory-hospital-pharmacy-purchases-b98794707a5a1a06Pharma Surgeen2026-07-07T09:46:36.000ZWhy Maharashtra FDA Banned Compulsory Hospital Pharmacy Purchaseshttps://www.pharmaradar360.com/article/how-do-analysts-rate-this-biotech-focused-on-chronic-inflammatory-diseases-f520bec606c17ccdPharma Surgeen2026-07-07T09:42:03.000ZHow Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases?https://www.pharmaradar360.com/article/french-clinical-stage-biotech-s-uc-drug-faces-best-in-disease-doubts-as-analyst-d86c752ba559c435Pharma Surgeen2026-07-07T09:42:03.000ZFrench Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filinghttps://www.pharmaradar360.com/article/sanyou-and-baiyunshan-xihe-sign-radiopharma-deal-b033b4660a487d03Pharma Surgeen2026-07-07T09:32:13.000ZSanyou and Baiyunshan Xihe sign radiopharma dealhttps://www.pharmaradar360.com/article/krazati-combo-misses-phase-iii-mark-in-colorectal-cancer-cf58bcd7ad2bf903Pharma Surgeen2026-07-07T09:32:13.000ZKrazati combo misses Phase III mark in colorectal cancerhttps://www.pharmaradar360.com/article/rare-japan-ip-court-opinion-request-probes-pharmaceutical-patent-rules-67d7f48bc86addcbPharma Surgeen2026-07-07T09:12:00.000ZRare Japan IP Court opinion request probes pharmaceutical patent ruleshttps://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7Pharma Surgeen2026-07-07T09:10:38.000ZWorking for DHSChttps://www.pharmaradar360.com/article/rotavirus-vaccination-programme-information-for-healthcare-practitioners-53785302d776c5f3Pharma Surgeen2026-07-07T09:02:11.000ZRotavirus vaccination programme: information for healthcare practitionershttps://www.pharmaradar360.com/article/cereno-scientific-completes-all-dosing-and-participant-visits-in-cs014-s-fda-ali-c871d670a450d89dPharma Surgeen2026-07-07T09:00:00.000ZCereno Scientific Completes All Dosing and Participant Visits in CS014’s FDA-Aligned PK-Bridging Study, Advancing Capital-Efficient Path Toward Phase IIb in PH-ILDhttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-july-2026-5cb6f6902269e1ecPharma Surgeen2026-07-07T08:43:44.000ZUK Clinical Research Delivery key performance indicators: data to July 2026https://www.pharmaradar360.com/article/woodberry-packaging-acquires-medica-and-curtis-strengthening-its-position-in-pha-8078b9fe1ab6d86ePharma Surgeen2026-07-07T08:40:23.000ZWoodberry Packaging acquires Medica and Curtis, strengthening its position in pharmaceutical and personal care packaginghttps://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-data-to-june-2026-5ce9d540fae1527cPharma Surgeen2026-07-07T08:40:01.000ZMedicine supply disruption statistics, UK: data to June 2026https://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-june-2026-95407ca4abeca4e9Pharma Surgeen2026-07-07T08:38:01.000ZUK Clinical Research Delivery key performance indicators: data to June 2026https://www.pharmaradar360.com/article/polio-global-eradication-nac-and-environmental-surveillance-28a88d7a1d6b4d94Pharma Surgeen2026-07-07T08:34:51.000ZPolio: global eradication, NAC and environmental surveillancehttps://www.pharmaradar360.com/article/2026-b7f2bfa19e6fb750Pharma Surgeen2026-07-07T08:31:22.000ZΕπιστημονικές εκδηλώσεις εσωτερικού Α΄ εξαμήνου 2026https://www.pharmaradar360.com/article/guidance-clinical-trials-for-medicines-roles-and-responsibilities-3e0684843843bbdcPharma Surgeen2026-07-07T08:23:12.000ZGuidance: Clinical trials for medicines: roles and responsibilitieshttps://www.pharmaradar360.com/article/as-ai-sectors-cooldown-biotech-breaks-out-6-stocks-quietly-outperform-feeb27629042d7bcPharma Surgeen2026-07-07T08:20:26.000ZAs AI Sectors Cooldown, BioTech Breaks Out: 6 Stocks Quietly Outperformhttps://www.pharmaradar360.com/article/biotech-layoffs-in-2026-trends-triggers-and-what-s-at-stake-7c47efcd2cd6ebbePharma Surgeen2026-07-07T08:17:47.000ZBiotech Layoffs in 2026: Trends, Triggers, and What’s at Stakehttps://www.pharmaradar360.com/article/decision-doxecitine-and-doxribtimine-in-the-treatment-of-thymidine-kinase-2-defi-98729cfb4ffb37fcPharma Surgeen2026-07-07T08:15:25.000ZDecision: Doxecitine and Doxribtimine in the treatment of thymidine kinase 2 deficiency (TK2d)https://www.pharmaradar360.com/article/why-customer-experience-centers-are-becoming-practical-infrastructure-for-life-s-18f4fb049a82176cPharma Surgeen2026-07-07T08:03:44.000ZWhy Customer Experience Centers are becoming practical infrastructure for life sciences innovation in Europehttps://www.pharmaradar360.com/article/your-medicine-bottle-is-getting-a-qr-code-and-it-could-actually-save-your-life-6899e9309924dedaPharma Surgeen2026-07-07T08:00:14.000ZYour Medicine Bottle Is Getting a QR Code — and It Could Actually Save Your Lifehttps://www.pharmaradar360.com/article/biovica-expands-master-services-agreement-with-a-current-customer-a-leading-glob-60d72aa05adb38a7Pharma Surgeen2026-07-07T08:00:00.000ZBiovica expands Master Services Agreement with a current customer, a leading global pharmaceutical company, to support next-generation oncology development.https://www.pharmaradar360.com/article/abl-bio-targets-december-phase-3-start-for-abl111-in-gastric-cancer-cab24dfeb858d0bfPharma Surgeen2026-07-07T07:43:37.000ZABL Bio targets December phase 3 start for ABL111 in gastric cancerhttps://www.pharmaradar360.com/article/korean-nf2-drug-candidate-trineumin-wins-fda-rare-pediatric-disease-designation-f49644b6fd0506d0Pharma Surgeen2026-07-07T07:43:14.000ZKorean NF2 drug candidate Trineumin wins FDA rare pediatric disease designationhttps://www.pharmaradar360.com/article/hospitals-forcing-exclusive-prescriptions-now-on-fda-s-radar-says-tukaram-mundhe-579b7a0f0c99c9b0Pharma Surgeen2026-07-07T07:38:39.000ZHospitals Forcing Exclusive Prescriptions Now On FDA's Radar, Says Tukaram Mundhehttps://www.pharmaradar360.com/article/abl-bio-targets-december-phase-3-start-for-abl111-in-gastric-cancer-d98b0383152e3d32Pharma Surgeen2026-07-07T07:36:24.000ZABL Bio targets December phase 3 start for ABL111 in gastric cancerhttps://www.pharmaradar360.com/article/abl-bio-to-begin-phase-3-clinical-trial-of-abl111-in-december-sanofi-risks-also-ec346c10ce89bae8Pharma Surgeen2026-07-07T07:18:06.000ZABL Bio to Begin Phase 3 Clinical Trial of 'ABL111' in December... Sanofi Risks Also Resolvedhttps://www.pharmaradar360.com/article/price-to-book-forward-of-jiangsu-cowin-biotech-co-ltd-class-a-sse-688426-22ac643d1b24eb05Pharma Surgeen2026-07-07T07:09:54.000ZPrice to book forward of Jiangsu Cowin Biotech Co., Ltd. Class A – SSE:688426https://www.pharmaradar360.com/article/sustained-release-polymers-market-advances-as-drug-delivery-innovation-reshapes-3cf8b187703c91e1Pharma Surgeen2026-07-07T07:01:55.000ZSustained Release Polymers Market Advances as Drug Delivery Innovation Reshapes Pharmaceutical Formulation Strategies with USD 7.8 Billion in 2036 | Future Market Insightshttps://www.pharmaradar360.com/article/abl-bio-pursues-big-pharma-deals-as-korea-advances-cancer-and-bbb-programs-chosu-4369581b0888c6b6Pharma Surgeen2026-07-07T06:59:00.000ZABL Bio pursues big pharma deals as Korea advances cancer and BBB programs - CHOSUNBIZhttps://www.pharmaradar360.com/article/samjin-pharm-launches-fulvestrant-injection-for-hr-her2-advanced-breast-cancer-55738b181e40e3efPharma Surgeen2026-07-07T06:42:09.000ZSamjin Pharm launches fulvestrant injection for HR+/HER2- advanced breast cancerhttps://www.pharmaradar360.com/article/italy-s-angels-incubators-and-venture-capital-weekly-roundup-news-from-banyan-bi-4cfd345637eec390Pharma Surgeen2026-07-07T06:31:06.000ZItaly’s angels & incubators and venture capital weekly roundup. News from Banyan Biotech, Berrier Capital and morehttps://www.pharmaradar360.com/article/french-gene-therapy-biotech-gets-33m-to-follow-krystal-s-blueprint-c63e060b6fd86bd4Pharma Surgeen2026-07-07T05:30:00.000ZFrench gene therapy biotech gets €33M to follow Krystal’s blueprinthttps://www.pharmaradar360.com/article/hc-questions-fda-push-to-invoke-mcoca-in-food-safety-cases-across-maha-6bbd93fbb79cdc4fPharma Surgeen2026-07-07T05:15:00.000ZHC questions FDA push to invoke MCOCA in food safety cases across Mahahttps://www.pharmaradar360.com/article/hc-questions-fda-push-to-invoke-mcoca-in-food-safety-cases-across-maha-46dc70bdb7397099Pharma Surgeen2026-07-07T05:07:02.000ZHC questions FDA push to invoke MCOCA in food safety cases across Mahahttps://www.pharmaradar360.com/article/gc-biopharma-wins-approval-for-domestic-phase-3-clinical-trial-of-two-dose-varic-a34fb9abe6db1443Pharma Surgeen2026-07-07T05:06:44.000ZGC Biopharma wins approval for domestic Phase 3 clinical trial of two-dose varicella vaccinehttps://www.pharmaradar360.com/article/drug-discovery-ai-moves-beyond-hype-to-an-r-d-productivity-test-578841b8458cb71bPharma Surgeen2026-07-07T05:02:25.000ZDrug discovery AI moves beyond hype to an R&D productivity testhttps://www.pharmaradar360.com/article/roche-presents-new-data-in-alzheimer-s-disease-from-across-its-integrated-pharma-859cacd0e13dbf48Pharma Surgeen2026-07-07T05:00:00.000ZRoche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIChttps://www.pharmaradar360.com/article/roche-presents-new-data-in-alzheimer-s-disease-from-across-its-integrated-pharma-f051c2312acd4eb2Pharma Surgeen2026-07-07T05:00:00.000ZRoche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIChttps://www.pharmaradar360.com/article/us-fda-confirms-alterity-s-phase-iii-trial-path-b6a08f225b300d0fPharma Surgeen2026-07-07T04:58:00.000ZUS FDA confirms Alterity’s Phase III trial pathhttps://www.pharmaradar360.com/article/the-clinical-trial-that-supported-tavneos-for-anca-vasculitis-was-just-retracted-b08c08b64d438a01Pharma Surgeen2026-07-07T04:54:42.000ZThe Clinical Trial That Supported Tavneos for ANCA Vasculitis Was Just Retractedhttps://www.pharmaradar360.com/article/drug-discovery-ai-moves-beyond-hype-to-an-r-d-productivity-test-de399667f7a3b694Pharma Surgeen2026-07-07T04:43:32.000ZDrug discovery AI moves beyond hype to an R&D productivity testhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-pci-biotech-holding-asa-ls-a0q2fs-39085cc0e3b2325bPharma Surgeen2026-07-07T04:25:35.000ZPrice to earnings forward of PCI Biotech Holding ASA – LS:A0Q2FShttps://www.pharmaradar360.com/article/matica-biotech-vaxdome-partner-to-advance-antiviral-vaccine-platform-into-clinic-1b8321a66b6e0a87Pharma Surgeen2026-07-07T04:03:43.000ZMatica Biotech, VaxDome partner to advance antiviral vaccine platform into clinichttps://www.pharmaradar360.com/article/fda-warns-of-fatal-liver-injuries-tied-to-drug-it-wants-pulled-from-market-8e7a5fdd0872d3a2Pharma Surgeen2026-07-07T04:02:58.000ZFDA warns of fatal liver injuries tied to drug it wants pulled from markethttps://www.pharmaradar360.com/article/glp-1-receptor-agonist-exposures-reported-to-poison-center-up-after-fda-approval-0c0be06290ebcdaePharma Surgeen2026-07-07T04:00:00.000ZGLP-1 Receptor Agonist Exposures Reported to Poison Center Up After FDA Approval for Weight Losshttps://www.pharmaradar360.com/article/infusion-pump-correction-fresenius-kabi-issues-correction-for-ivenix-large-volum-096ffb752898b3d2Pharma Surgeen2026-07-07T04:00:00.000ZInfusion Pump Correction: Fresenius Kabi Issues Correction for Ivenix Large Volume Infusion Pumphttps://www.pharmaradar360.com/article/infusion-pump-correction-fresenius-kabi-issues-correction-for-dropped-or-jarred-e0bb70b4f5aa3d10Pharma Surgeen2026-07-07T04:00:00.000ZInfusion Pump Correction: Fresenius Kabi Issues Correction for dropped or jarred Ivenix Large Volume Infusion Pumpshttps://www.pharmaradar360.com/article/vertex-signs-letter-of-intent-loi-with-the-pan-canadian-pharmaceutical-alliance-32248ff88480cc43Pharma Surgeen2026-07-07T03:47:20.000ZVertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosishttps://www.pharmaradar360.com/article/three-biotech-stocks-crushed-the-s-p-500-analysts-still-back-just-one-1cf415a0b004cc3ePharma Surgeen2026-07-07T03:32:34.000ZThree Biotech Stocks Crushed the S&P 500 — Analysts Still Back Just Onehttps://www.pharmaradar360.com/article/texas-pushes-forward-with-state-ibogaine-research-program-after-failing-to-find-4ae613fb9cd76c18Pharma Surgeen2026-07-07T03:11:00.000ZTexas pushes forward with state ibogaine research program after failing to find drug company partnerhttps://www.pharmaradar360.com/article/aribio-to-unveil-new-ar1001-data-at-alzheimer-s-conference-998851679b5c101bPharma Surgeen2026-07-07T03:05:29.000ZAriBio to unveil new AR1001 data at Alzheimer's conferencehttps://www.pharmaradar360.com/article/alterity-therapeutics-clears-key-fda-hurdle-for-ath434-phase-3-pathway-7241ff566c6d5df4Pharma Surgeen2026-07-07T03:03:41.000ZAlterity Therapeutics clears key FDA hurdle for ATH434 Phase 3 pathwayhttps://www.pharmaradar360.com/article/anzen-mhlw-pharmaceuticals-and-medical-devices-safety-information-no-429-posted-d1435f2c2e88bb2fPharma Surgeen2026-07-07T03:00:00.000Z[ANZEN]MHLW Pharmaceuticals and Medical Devices Safety Information No.429 postedhttps://www.pharmaradar360.com/article/china-s-national-medical-products-administration-accepts-biologics-license-appli-00dae1ff100e152fPharma Surgeen2026-07-07T02:30:00.000ZChina’s National Medical Products Administration Accepts Biologics License Application for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/belite-bio-blte-after-new-phase-3-data-news-and-the-case-for-fair-value-1f609f0996a22856Pharma Surgeen2026-07-07T01:34:36.000ZBelite Bio (BLTE) After New Phase 3 Data News And The Case For Fair Valuehttps://www.pharmaradar360.com/article/us-based-malayali-carves-a-niche-with-knee-treatment-255854012aa5998cPharma Surgeen2026-07-07T01:30:39.000ZUS-based Malayali carves a niche with knee treatmenthttps://www.pharmaradar360.com/article/ila-s-drug-approved-for-urgent-use-in-the-current-ongoing-major-ebola-outbreak-f-7d9e8d3b10cd7e2dPharma Surgeen2026-07-07T00:03:00.000ZILA’s drug approved for urgent use in the current ongoing major Ebola outbreak. Funded trial to generate rare human data in emergency, real world deadly virus outbreak situation.https://www.pharmaradar360.com/article/vertex-pharmaceuticals-filed-form-8-k-7c7fb8b633423119Pharma Surgeen2026-07-07T00:00:00.000ZVertex Pharmaceuticals filed Form 8-Khttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-6eefe1e61c1295bdPharma Surgeen2026-07-07T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/new-technologies-could-help-cut-years-long-wait-for-endometriosis-diagnosis-says-528e4e37e26bada6Pharma Surgeen2026-07-07T00:00:00.000ZNew technologies could help cut years-long wait for endometriosis diagnosis, says NICEhttps://www.pharmaradar360.com/article/new-animal-drugs-approval-of-new-animal-drug-applications-withdrawal-of-approval-fec0647368369f3aPharma Surgeen2026-07-07T00:00:00.000ZNew Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsorhttps://www.pharmaradar360.com/article/office-of-the-secretary-notice-of-meeting-c0ba619840c46db4Pharma Surgeen2026-07-07T00:00:00.000ZOffice of the Secretary; Notice of Meetinghttps://www.pharmaradar360.com/article/recission-of-the-national-cancer-institute-clinical-cancer-education-program-reg-be11376bf7623390Pharma Surgeen2026-07-07T00:00:00.000ZRecission of the National Cancer Institute Clinical Cancer Education Program Regulationhttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-benuvia-operations-llc-d13da85284e18846Pharma Surgeen2026-07-07T00:00:00.000ZImporter of Controlled Substances Application: Benuvia Operations, LLC.https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-7de317d9222efac3Pharma Surgeen2026-07-07T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-00497debdfd6bcd2Pharma Surgeen2026-07-07T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-3c67d0de69b46fa0Pharma Surgeen2026-07-07T00:00:00.000ZMedicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardihttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-ee8f225175e0aad8Pharma Surgeen2026-07-07T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Rural Health Care Services Outreach Program Measures, OMB No. 0906-0009-Revisionhttps://www.pharmaradar360.com/article/national-institute-of-diabetes-and-digestive-and-kidney-diseases-amended-notice-230aa57d07ee67a4Pharma Surgeen2026-07-07T00:00:00.000ZNational Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/ars-pharmaceuticals-announces-ceo-succession-4ed39be05107e8c8Pharma Surgeen2026-07-07T00:00:00.000ZARS Pharmaceuticals Announces CEO Successionhttps://www.pharmaradar360.com/article/ways-to-avoid-getting-sick-when-traveling-b5d9ed84f77a067dPharma Surgeen2026-07-07T00:00:00.000ZWays to Avoid Getting Sick When Travelinghttps://www.pharmaradar360.com/article/cleveland-clinic-expanding-saturday-surgery-and-procedure-offerings-1cb0a73898abd437Pharma Surgeen2026-07-07T00:00:00.000ZCleveland Clinic Expanding Saturday Surgery and Procedure Offerings